eight-five patients receiving cytosine arabinoside and daunorubicin as induction therapy of acute myelogenous leukemia were randomly assigned to receive lithium carbonate 300 mg t.i.d . or no lithium .
C0011015
daunorubicin
C0023467
acute myelogenous leukemia